Foster Wheeler (FWLT) Awarded Contract by Hungarian Biopharma KEDIRON
More News related to FWLT
- Foster Wheeler to Supply Condensers to Lilama for Thermal Power Plant in Vietnam
- Foster Wheeler Awarded PMC Contract for LNG Terminal in Singapore
- Foster Wheeler (FWLT) Unit Awarded Contract by The Government of the Republic of Uganda
- Foster Wheeler Wins Oil Refinery Feasibility Study in Uganda
- Foster Wheeler and SOFCON to Form Joint Venture in Saudi Arabia
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Foster Wheeler AG (NASDAQ: FWLT) announced today that its Global Engineering and Construction Group has been awarded by KEDRION GROUP and its Hungarian-controlled HUMAN BIOPLAZMA LLC. a contract for engineering, procurement, construction management and commissioning/qualification supervision for the upgrading and expansion of a bulk plasma fractionation manufacturing facility at Godollo, Hungary.
KEDRION is a biopharmaceutical company specializing in the development, manufacture and distribution of plasma-derived medicinal products.
The Foster Wheeler contract value for this project was not disclosed and was included in the company's second-quarter 2009 bookings.
The contract consists of the upgrading and capacity expansion of an existing plasma fractionation plant in line with Good Manufacturing Practice (GMP), including the installation of a new production line. During the upgrading works, the existing line will remain in operation. The plant is expected to be completed in the first quarter of 2011.
"We are very pleased to assign the execution
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
